Form 4 for MNPR Monopar Therapeutics

Accepted 2026-08-27 19:29:11 ET · period of report 2026-08-26 · accession 0001437749-26-029121 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DT	2026-08-27 19:29	2026-08-26	MNPR	RIOUX PATRICE	Acting Chief Medical Off	M - OptEx	$0.005	+1,380	5,066	+37%	+$6.90
DT	2026-08-27 19:29	2026-08-26	MNPR	RIOUX PATRICE	Acting Chief Medical Off	S - Sale+OE	$111.26	-1	5,065	-0.0%	-$111.26
DT	2026-08-27 19:29	2026-08-26	MNPR	RIOUX PATRICE	Acting Chief Medical Off	M - OptEx	$0.00	+1,380	0	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-08-26	M	A	1,380	$0.005	5,066	D	—	—	(F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
2	Common	Common Stock	2026-08-26	S	D	1	$111.26	5,065	D	—	—	(F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
3	Derivative	Stock Option	2026-08-26	M	A	1,380	$0.00	0	D	$0.005 · — to 2026-12-14	1,380 Common Stock	(F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. (F2) On December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of common stock vested: 238 shares on January 15, 2017; 224 shares on February 15, 2017; 238 shares on March 15, 2017; 224 shares on April 15, 2017; 238 shares on May 15, 2017; and 238 shares on June 15, 2017.